BCM-95® (CURCUGREEN®), 07 Aug 2021
Homa Hodaei, Mahsa Adibian, Omid Nikpayam, Mehdi Hedayati and Golbon Sohrab
Background: Diabetes mellitus is a common metabolic disorders in human and afect a lot of people around the world. Curcumin is a component of turmeric and in many studies therapeutic efects such as anti-hypertensive, antihyperlipidemia, anti-hyperglycemia for this substance are shown.
Aim: The aim of this study was to investigate the efect of curcumin supplementation on anthropometric indices glycemic control and oxidative stress in overweight patients with type 2 diabetes.
Materials and methods: In this randomized, double-blind, placebo-controlled trial, 53 participants with type 2 diabetes were divided randomly into the experimental and control groups to receive either 1500 mg curcumin or placebo capsule three times in a day for 10 weeks.
Result: Supplementation with curcumin in type 2 diabetes compare to placebo causes a signifcant changes in mean weight (−0.64±0.22 vs. 0.19±0.37 p<0.05), body mass index (BMI) (0.3±0.03 vs. 0.1±0 p<0.05), waist circumference (WC) (−1.2±0.4 vs. −0.43±0.11 p<0.05) and fasting blood sugar (FBS) (−7±2 vs. 3±0.2 p<0.05) but did not show any diference for hemoglobin A1c (HbA1c), insulin, malondialdehyde (MDA), total antioxidant capacity
(TAC), Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and pancreatic B cell function (HOMA-B) at end of study.
Conclusion: This study indicated that daily administration of 1500 mg curcumin has positive efects in reducing fasting blood glucose and weight in patients with type 2 diabetes.
Trial registration NCT02529982. Registered 19 August 2015, http://www.clinicaltrial.gov